Effect of variants in COMT and UGT1A genes on clinical response in patients with Parkinson’s disease treated with opicapone
Objective: To identify genetic variants associated with different clinical responses in patients with Parkinson’s disease(PD) treated with opicapone. Background: Opicapone is a catechol‐O‐methyltransferase(COMT) inhibitor used…Improvements in Parkinson’s disease motor complications after treatment with opicapone: results from the OPTI-ON study
Objective: To describe motor complications as measured by the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Part IV in participants from the Opicapone Treatment…Combination COMT inhibitor with Levodopa reduces consumption of vitamin B6
Objective: To investigate changes in Levodopa (LD) pharmacokinetics and changes in homocysteine, vitamin B6, and vitamin B12 in Parkinson's disease (PD) patients receiving LD formulations…ADOPTION Study: Status update of a Randomised, Open-Label Exploratory Trial of Opicapone in Parkinson’s Disease
Objective: This study aims to evaluate the effect of once-daily opicapone (OPC) 50 mg versus an additional dose of levodopa (L-dopa)/dopa decarboxylase inhibitor (DDCi) to…Open-Label, Single-Arm, Exploratory Trial of Opicapone: Status Update of the OASIS (OPICAPONE IN SLEEP DISORDER) Study
Objective: This study aims to evaluate the effects of opicapone (OPC) 50 mg treatment on sleep disorders in patients with Parkinson’s disease (PD) and ‘wearing-off’.…COMT polymorphism as a genetic factor in levodopa-induced dyskinesia development in Russian patients with Parkinson’s disease
Objective: We examined the influence of single nucleotide polymorphisms (SNPs) in specific genes on levodopa-induced dyskinesia development in Parkinson’s disease patients Background: Levodopa-induced dyskinesia (LID)…Clinical and genetic analysis of psychosis in Parkinson’s disease
Objective: This study aimed to examine the association of seven selected polymorphisms of DRD2, ANKK1, COMT and DAT genes with Parkinson’s disease psychosis (PDP) onset.…OPTIMIPARK Questionnaire:a tool to optimize treatment in Parkinson´s disease.
Objective: To validate the OPTIMIPARK questionnaire as a tool to help the clinician in the adjustment of dopaminergic treatment in Parkinson´s disease(PD). Background: At early…Opicapone in fluctuating Parkinson’s disease: The daily clinical practice
Objective: To evaluate the effectiveness, tolerability and safety of opicapone as add-on to levodopa (LD) in the daily clinical practice in fluctuating Parkinson’s disease (PD)…Opicapone added to safinamide in patients affected by Parkinson’s disease for better controlling motor fluctuations
Objective: The aim of this clinical observation was to verify the sparing of levodopa in patients affected by Parkinson's disease who already started safinamide treatment for…